Skip to main content

Chronic Pelvic Pain

Chronic pelvic pain (CPP) is a highly prevalent, multifactorial syndrome — not a single disease — that affects roughly 15–26% of women and ~9.3% of men (as chronic prostatitis / chronic pelvic pain syndrome, CP/CPPS). It is defined as pain perceived to originate from pelvic structures lasting ≥ 6 months (or ≥ 3 months in men per NIH criteria), often associated with urinary, bowel, sexual, and psychological dysfunction. The origin is not gynecologic in ~80% of female patients, and the most common contributors across both sexes are irritable bowel syndrome, bladder pain syndrome / interstitial cystitis, myofascial pelvic floor dysfunction, and endometriosis (in women). The cornerstone of management is a biopsychosocial, multimodal, interdisciplinary approach.[1][2][3][4][5]

For the bladder-specific phenotype, see IC/PBS; for menopause-related pelvic and urogenital pain, see Genitourinary Syndrome of Menopause.

Part I — Conceptual Framework​

Definition​

  • Women: pain perceived to originate from pelvic organs/structures lasting > 6 months, with negative cognitive, behavioral, sexual, and emotional consequences. Cyclical pain (e.g., dysmenorrhea) is included if it carries significant functional impact.[1][3]
  • Men (CP/CPPS): pelvic pain or discomfort for ≥ 3 months in the absence of identifiable infection, cancer, urinary obstruction, or retention.[4][6]

Epidemiology​

  • Women — prevalence 5.7–26% globally; accounts for 40% of diagnostic laparoscopies and 12–39% of hysterectomies in the US[2][7]
  • Men — CP/CPPS lifetime prevalence ~9.3%; ~267,000 US men diagnosed annually; risk rises after age 50[4][6]

Pathophysiology — the biopsychosocial model​

CPP is best understood as a chronic pain syndrome with three interacting domains:[1][2]

  1. Peripheral pain generators — visceral (gynecologic, urologic, GI) and somatic (musculoskeletal, neural) nociceptive input
  2. Central sensitization — amplified spinal/brain pain signaling, decreased descending inhibition, viscero-visceral and viscero-somatic convergence
  3. Psychosocial modulation — mood disorders, trauma, catastrophizing, sleep disruption, social stressors

Central sensitization explains why pain persists after treating the primary lesion (e.g., endometriosis excision), why CPP overlaps with IBS / IC/BPS / fibromyalgia / migraine, and why purely organ-targeted treatment frequently fails.[2][5]

Part II — Etiology by Organ System​

A. Gynecologic (women)​

ConditionNotes
EndometriosisDysmenorrhea, dyspareunia, non-menstrual pelvic pain; affects ~10% of reproductive-age women; 33–50% of CPP cases[1][8][9]
AdenomyosisDysmenorrhea, heavy bleeding, diffusely enlarged uterus; often coexists with endometriosis[3]
VulvodyniaChronic vulvar pain (burning, stinging) without identifiable cause; provoked or unprovoked; 8–16% of women
Pelvic massesFibroids, ovarian cysts — pressure / bulk-related pain
Chronic pelvic infectionHistory of PID; tubal damage and adhesions

Endometriosis deserves emphasis — affects ~10% of reproductive-age women (~9 million in the US); 90% report pelvic pain; diagnostic delay averages 5–12 years. Pain mechanisms include nociceptive (inflammation), neuropathic (nerve infiltration / neurogenesis), and nociplastic (central sensitization) — explaining why lesion burden correlates poorly with pain severity and why ~25% have recurrent pain after hysterectomy.[8][9]

B. Urologic (both sexes)​

Bladder pain syndrome / interstitial cystitis (BPS/IC)​

  • Persistent or chronic discomfort perceived as bladder origin, with urgency or frequency, lasting ≥ 6 weeks with negative urine cultures[10]
  • More commonly diagnosed in women; increasingly recognized in men (often misdiagnosed as CP/CPPS)[10][11]
  • Hunner lesions (~5–10%) represent a distinct phenotype with different treatment responses[10][12]
  • The 2022 AUA IC/BPS guideline replaced tiered treatment lines with categorical management — see IC/PBS for the full algorithm[10][11][13]

Chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS) — men​

  • The most common urologic diagnosis in men < 50[4][14]
  • Diagnosis of exclusion — made when history, exam, urine culture, and PVR exclude infection, cancer, obstruction, and retention[4]
  • NIH-CPSI measures symptom severity (0–43 scale); a 6-point change is clinically meaningful[4]
  • Pelvic floor myalgia / tenderness in 27–64% of CP/CPPS patients[4]
  • Higher rates of fibromyalgia, chronic fatigue, IBS, depression, anxiety, and panic disorder[6]

C. Gastrointestinal​

  • Irritable bowel syndrome (IBS) — most common GI cause of CPP; present in 35–50% of CPP patients[1][2]
  • Diverticular disease, IBD, chronic constipation may all contribute[1]

D. Musculoskeletal and myofascial​

  • Found in 50–90% of women at specialized CPP centers when musculoskeletal exam is performed[2]
  • Pelvic floor myalgia — hypertonicity, trigger points, inability to voluntarily relax pelvic floor
  • Abdominal-wall myofascial pain — trigger points in rectus and obliques; positive Carnett sign
  • Sacroiliac, hip, and lumbar spine disorders may refer pain to the pelvis[1]
  • The most commonly overlooked contributor — focus on visceral causes alone leads to prolonged pain and unnecessary surgery[2]

E. Neurologic​

Pudendal neuralgia​

Chronic neuropathic pain in the pudendal nerve distribution (perineum, vulva/scrotum, perianal region).[15][16][17]

Nantes diagnostic criteria:[15][16]

  1. Pain in the anatomical territory of the pudendal nerve
  2. Pain worsened by sitting
  3. Pain does not wake the patient at night
  4. No objective sensory loss on exam
  5. Positive response to a diagnostic pudendal nerve block

Etiologies: entrapment (Alcock canal, sacrospinous / sacrotuberous ligaments), childbirth, pelvic surgery, cycling, sacroiliac abnormalities.[15][17][18]

Stepwise management:[15][16][17]

  1. Conservative — avoid prolonged sitting, cushion, pelvic floor PT
  2. Pharmacologic — TCAs or gabapentinoids first-line; opioids ineffective[16]
  3. Pudendal nerve blocks — diagnostic and therapeutic; response rates up to 94%[15]
  4. Pulsed radiofrequency — pain reduction in up to 95% of refractory cases; long-term durability uncertain[15][19]
  5. Surgical decompression — refractory cases (transgluteal, transischiorectal, transperineal)[15][16]
  6. Sacral or pudendal neuromodulation — refractory cases[16][17]

Other neuralgias — ilioinguinal, iliohypogastric, genitofemoral entrapment, particularly after pelvic / abdominal surgery or mesh.[2]

F. Vascular — pelvic congestion syndrome (PCS)​

  • Chronic pelvic pain associated with pelvic varicosities from incompetent ovarian / pelvic vein valves[20][21][22][23]
  • Estimated to account for up to 30% of CPP in women, although ACOG notes the evidence is insufficient to confirm a causal relationship[20][1]
  • Phenotype: dull aching pelvic pain worsened by prolonged standing, post-coital pain, premenstrual exacerbation; predominantly premenopausal, parous women[20][21][23]
  • Pathophysiology: ovarian/pelvic vein valve incompetence → retrograde flow → venous hypertension and dilation; may be secondary to nutcracker (left renal vein compression) or May-Thurner (iliac vein compression)[21][22]
  • Diagnosis:[20][22][24]
    • TVUS — first-line; ovarian vein diameter > 7–8 mm, slow / retrograde flow, dilated (> 5 mm) pelvic veins
    • Venography — gold standard but invasive
    • MRI / CT — dilated pelvic veins seen in 12% of women on CT (21% premenopausal, 10% postmenopausal)[24]
    • Caveat: laparoscopy has limited sensitivity because CO₂ pneumoperitoneum compresses the veins[20]
  • Treatment:[21][22][23]
    • Ovarian vein embolization — minimally invasive, first-choice; excellent technical and clinical success
    • Hormonal suppression — medroxyprogesterone may reduce pain
    • Venous stenting — for obstructive nutcracker / May-Thurner
    • Hysterectomy + BSO — historical; largely replaced by embolization

G. Psychosocial​

  • Depression in 12–33% of women with CPP[1]
  • Trauma history — pelvic pain and dyspareunia more prevalent in women with abuse, military sexual trauma, or adverse childhood events[1][2]
  • Catastrophizing and anxiety independently predict pain severity and disability[25]
  • Psychosocial factors do not change the physical pain generators but amplify the symptom burden and impair recovery[1]

Part III — Clinical Phenotyping (Men): UPOINT​

The UPOINT system is the most widely adopted clinical phenotyping tool for CP/CPPS, sorting patients into six domains to drive individualized, multimodal therapy.[25][26][27][28][29]

DomainDescriptionTargeted treatment
U — UrinaryVoiding / storage symptomsAlpha-blockers (tamsulosin, alfuzosin)
P — PsychosocialDepression, catastrophizing, anxiety, maladaptive copingCBT, antidepressants, psychological support
O — Organ-specificProstate / bladder tenderness, Hunner lesionsAnti-inflammatories, quercetin, intravesical therapy
I — InfectionDocumented localized infectionTargeted antibiotics — only if proven
N — Neurologic / SystemicWidespread pain, fibromyalgia, central sensitizationGabapentinoids, SNRIs, pain-mechanism education
T — TendernessPelvic floor muscle tenderness, trigger pointsPelvic floor PT, myofascial release

The number of positive UPOINT domains correlates with NIH-CPSI severity. Cluster analysis identifies a pelvic-predominant cluster (U, O, T) and a systemic cluster (N, I, P); the dominant pain drivers across patients are pelvic floor tenderness, depression, and catastrophizing.[25] A sexual-dysfunction domain (S) has been added (UPOINTS) to improve stratification.[26]

Part IV — Diagnostic Evaluation​

Women​

  1. Biopsychosocial history — pain (onset, location, quality, severity, triggers, menstrual relationship), urinary / GI / sexual symptoms, trauma history, mood / sleep, prior treatments[2][3][5]
  2. Red-flag screening — acute abdomen, unintentional weight loss, postmenopausal bleeding, hematuria, rectal bleeding, new neurologic deficit → urgent evaluation
  3. Physical exam — abdominal (Carnett test for abdominal-wall pain); pelvic musculoskeletal exam of levator ani, obturator internus, and piriformis for trigger points and hypertonicity; neurosensory mapping; speculum and bimanual exam for masses, tenderness, prolapse, endometriosis nodularity
  4. Basic diagnostics — pregnancy test, UA / culture, STI screen, transvaginal ultrasound
  5. Advanced imaging — MRI for suspected endometriosis, adenomyosis, complex masses; TVUS with vascular assessment for PCS
  6. Assess for central sensitization — widespread pain, multiple pain syndromes, allodynia / hyperalgesia, sleep / mood disturbance

Men​

  1. History — pain location / quality / duration, voiding symptoms, sexual dysfunction, psychosocial impact[4][28]
  2. Physical exam — DRE (prostate tenderness), pelvic floor palpation (external and internal)
  3. Urine culture (exclude infection); PVR (exclude retention)
  4. NIH-CPSI for symptom severity
  5. UPOINT phenotyping to guide treatment
  6. Consider cystoscopy, urodynamics, transrectal ultrasound if uncertainty

Part V — Management​

Overarching principles (both sexes)[1][2][3][30]​

  • Multimodal interdisciplinary treatment is superior to single-agent therapy or surgery alone
  • Patient education about pain mechanisms (especially central sensitization) is essential
  • Shared decision-making with functional goal-setting
  • Treat all contributing domains simultaneously — visceral, myofascial, neurologic, psychosocial
  • Opioids are not recommended for CPP

A. Non-pharmacologic therapies​

TherapyEvidence
Pelvic floor PTHigh-certainty evidence in women (SMD −1.69 for short-term pain); effective in both sexes; recommended by ACOG, AUA, EAU[1][30][31][32]
CBTSmall-to-moderate benefit for chronic pain syndromes; addresses catastrophizing, depression, anxiety[2][30]
Sex therapyAdjunct to PT for dyspareunia and genito-pelvic pain[1]
Self-managementModerate physical activity, stress management, mindfulness, dietary modification[2]
AcupunctureMay be considered for musculoskeletal CPP (ACOG Level C); evidence inconsistent[1][33]

B. Pharmacologic therapies​

ClassAgentsEvidence / indication
Alpha-blockersTamsulosin, alfuzosinFirst-line for CP/CPPS with urinary symptoms; ΔNIH-CPSI −10.8 to −4.8 vs placebo[4][26]
NSAIDsIbuprofen, naproxenModest benefit in CP/CPPS (ΔNIH-CPSI −2.5 to −1.7); modest benefit in dysmenorrhea; no proven benefit in endometriosis[4][8][9]
SNRIsDuloxetine, venlafaxineRecommended for neuropathic CPP (ACOG Level B); no CPP-specific RCTs[1][2]
GabapentinoidsGabapentin, pregabalinRecommended for neuropathic CPP (ACOG Level B); pregabalin ΔNIH-CPSI −2.4 in CP/CPPS; one large CPP RCT showed no significant pain improvement[1][2][34]
TCAsAmitriptyline, nortriptylineFirst-line for IC/BPS and pudendal neuralgia; weaker evidence in general CPP[2][10]
Hormonal therapyCOCs, progestins, GnRH agonists / antagonistsFirst-line for endometriosis-related CPP; continuous use preferred[8][9][34][35]
PhytotherapyPollen extract (Cernilton)Modest benefit in CP/CPPS (ΔNIH-CPSI −2.49)[26]
PDE5 inhibitorsTadalafilLimited evidence in CP/CPPS[26]
Muscle relaxantsCyclobenzaprine, intravaginal diazepamInsufficient / inconsistent evidence for myofascial CPP[2]
  • First-line: combined oral contraceptives (continuous use preferred) or progestins (norethindrone acetate, dienogest, LNG-IUS) — clinically significant pain reduction (MD −12.6 to −17.7 on 0–100 VAS vs placebo)
  • Second-line: GnRH agonists (leuprolide) or antagonists (elagolix, relugolix combination) with add-back therapy
  • Third-line: aromatase inhibitors (letrozole, anastrozole) — off-label
  • Limitation: 25–34% recur within 12 months of stopping hormonal therapy; 11–19% have no pain reduction with hormonal medications

D. Interventional therapies​

  • Trigger point injections (saline, anesthetic, steroid, or botulinum toxin A) for myofascial CPP — ACOG Level B[1][2]
  • Pudendal nerve blocks — diagnostic and therapeutic; up to 94% response in pudendal neuralgia[15]
  • Sacral neuromodulation — emerging evidence for refractory IC/BPS and CPP[13]
  • Pulsed radiofrequency — 95% pain reduction in refractory pudendal neuralgia[15][19]
  • Ovarian vein embolization — first-choice for PCS[21][22]

E. Surgical therapies​

Women:

  • Laparoscopic excision of endometriosis when hormonal therapies are ineffective or contraindicated; ~25% have recurrent pain even after hysterectomy[8][36]
  • Hysterectomy — refractory endometriosis / adenomyosis with other treatments exhausted; ovarian preservation in premenopausal women when feasible[8][36]
  • Laparoscopic adhesiolysis is NOT recommended — no benefit and may worsen outcomes (ACOG Level A)[1][30]
  • LUNA and presacral neurectomy do NOT improve CPP[30]
  • Pudendal nerve decompression — refractory pudendal neuralgia after failed conservative / interventional therapy[15][16]

Men:

  • The 2025 AUA male CPP guideline recommends initial non-surgical therapy with shared decision-making; surgery is not first-line[32]
  • Transurethral procedures (e.g., TURP) are not recommended for CP/CPPS

F. AUA male CPP guideline (2025) — multimodal pathway[4][28][32]​

  1. Alpha-blockers for urinary symptoms
  2. NSAIDs for pain / inflammation
  3. Pregabalin for neurologic / systemic symptoms
  4. Pollen extract as a phytotherapy option
  5. Pelvic floor PT for the tenderness domain (27–64% of patients)
  6. CBT / psychological support for the psychosocial domain
  7. Antibiotics are NOT recommended without proven infection
  8. Referral to specialists for psychosocial impairment and chronic non-urologic pain (fibromyalgia, IBS)

Part VI — Special Topics​

Chronic overlapping pain conditions (COPCs)​

CPP frequently coexists with other chronic pain syndromes, reflecting shared central-sensitization mechanisms:[2][5][6]

  • Fibromyalgia
  • IBS
  • IC/BPS
  • Chronic fatigue syndrome
  • Migraine / tension headaches
  • Temporomandibular disorders
  • Vulvodynia

The presence of multiple COPCs suggests a nociplastic phenotype in which central sensitization dominates — these patients benefit more from centrally-acting therapies (gabapentinoids, SNRIs, CBT) than from organ-specific peripheral treatments.[2][5]

Sex-specific differences​

WomenMen
Prevalence15–26%~9.3% (CP/CPPS)
Most common causesIBS, IC/BPS, endometriosis, myofascialCP/CPPS, IC/BPS, myofascial
Hormonal contributionMajor (endometriosis, adenomyosis, cyclic pain)Minor
Pelvic floor involvement50–90%27–64%
Phenotyping toolBiopsychosocial frameworkUPOINT(S) system
Surgical optionsEndometriosis excision, hysterectomy (refractory)Not first-line; no established surgical role
Psychological burdenDepression 12–33%; trauma history commonDepression, anxiety, panic disorder elevated

Key Principles​

  • CPP is a syndrome, not a single disease — most patients have multiple contributing conditions[2][3]
  • Central sensitization is the unifying mechanism explaining pain persistence, COPC overlap, and poor response to organ-specific treatment alone[2]
  • Musculoskeletal / myofascial dysfunction is present in 50–90% of women and 27–64% of men — and is the most commonly overlooked contributor[2][4]
  • Biopsychosocial, multimodal, interdisciplinary treatment is essential[1][2]
  • Multimodal pelvic floor PT has the strongest evidence (high certainty) among non-pharmacologic treatments[31]
  • Opioids are not recommended for CPP in either sex[1][2]
  • Hormonal therapy is first-line for endometriosis-related CPP but does not address non-gynecologic pain generators[8]
  • Alpha-blockers are first-line for CP/CPPS with urinary symptoms[4]
  • Antibiotics should not be used for CP/CPPS without proven infection[28]
  • Laparoscopic adhesiolysis, LUNA, and presacral neurectomy are not recommended — they don't improve CPP and may worsen outcomes[1][30]
  • Pelvic congestion syndrome may account for up to 30% of CPP in women but remains controversial — ACOG considers the evidence insufficient to confirm causation[1][20]

References​

1. American College of Obstetricians and Gynecologists. "Chronic pelvic pain: ACOG Practice Bulletin, Number 218." Obstet Gynecol. 2020;135(3):e98–e109. doi:10.1097/AOG.0000000000003716

2. Lamvu G, Carrillo J, Ouyang C, Rapkin A. "Chronic pelvic pain in women: a review." JAMA. 2021;325(23):2381–2391. doi:10.1001/jama.2021.2631

3. As-Sanie S, Ross WT, Till SR. "Evaluation and treatment of chronic pelvic pain." Obstet Gynecol. 2025. doi:10.1097/AOG.0000000000006123

4. Borgert BJ, Wallen EM, Pham MN. "Prostatitis." JAMA. 2025;334(11):1003–1013. doi:10.1001/jama.2025.11499

5. Meisenheimer ES, Carnevale AM. "Chronic pelvic pain in women: evaluation and treatment." Am Fam Physician. 2025;111(3):218–229.

6. Voelker R. "What is prostatitis?" JAMA. 2026. doi:10.1001/jama.2025.20559

7. Leonardi M, Armour M, Gibbons T, et al. "Surgical interventions for the management of chronic pelvic pain in women." Cochrane Database Syst Rev. 2021;12:CD008212. doi:10.1002/14651858.CD008212.pub2

8. As-Sanie S, Mackenzie SC, Morrison L, et al. "Endometriosis." JAMA. 2025;334(1):64–78. doi:10.1001/jama.2025.2975

9. Zondervan KT, Becker CM, Missmer SA. "Endometriosis." N Engl J Med. 2020;382(13):1244–1256. doi:10.1056/NEJMra1810764

10. Clemens JQ, Erickson DR, Varela NP, Lai HH. "Diagnosis and treatment of interstitial cystitis/bladder pain syndrome." J Urol. 2022;208(1):34–42. doi:10.1097/JU.0000000000002756

11. Chermansky CJ, Guirguis MO. "Pharmacologic management of interstitial cystitis/bladder pain syndrome." Urol Clin North Am. 2022;49(2):273–282. doi:10.1016/j.ucl.2022.01.003

12. Imamura M, Scott NW, Wallace SA, et al. "Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis." Cochrane Database Syst Rev. 2020;7:CD013325. doi:10.1002/14651858.CD013325.pub2

13. Buford K, Peters KM, Riedl C, et al. "Global consensus on interstitial cystitis/bladder pain syndrome: an update on therapeutic treatments." Neurourol Urodyn. 2025. doi:10.1002/nau.70106

14. Pena VN, Engel N, Gabrielson AT, Rabinowitz MJ, Herati AS. "Diagnostic and management strategies for patients with chronic prostatitis and chronic pelvic pain syndrome." Drugs Aging. 2021;38(10):845–886. doi:10.1007/s40266-021-00890-2

15. Ahmed M, Zavridis P, Hadjiconstanti D, Zis P. "The diagnosis and management of pudendal neuralgia." Pain Ther. 2026;15(1):97–129. doi:10.1007/s40122-025-00803-w

16. Levesque A, Bautrant E, Quistrebert V, et al. "Recommendations on the management of pudendal nerve entrapment syndrome: a formalised expert consensus." Eur J Pain. 2022;26(1):7–17. doi:10.1002/ejp.1861

17. Conic RRZ, Kaur P, Kohan LR. "Pudendal neuralgia: a review of the current literature." Curr Pain Headache Rep. 2025;29(1):38. doi:10.1007/s11916-024-01354-z

18. Pérez-López FR, Hita-Contreras F. "Management of pudendal neuralgia." Climacteric. 2014;17(6):654–656. doi:10.3109/13697137.2014.912263

19. Petrov-Kondratov V, Chhabra A, Jones S. "Pulsed radiofrequency ablation of pudendal nerve for treatment of a case of refractory pelvic pain." Pain Physician. 2017;20(3):E451–E454.

20. Krambeck C, Tesch K, Watrowski R, Maass N, Alkatout I. "Pelvic congestion syndrome: the gynecological perspective." J Clin Med. 2026;15(4):1655. doi:10.3390/jcm15041655

21. Bałabuszek K, Toborek M, Pietura R. "Comprehensive overview of the venous disorder known as pelvic congestion syndrome." Ann Med. 2022;54(1):22–36. doi:10.1080/07853890.2021.2014556

22. Bookwalter CA, VanBuren WM, Neisen MJ, Bjarnason H. "Imaging appearance and nonsurgical management of pelvic venous congestion syndrome." Radiographics. 2019;39(2):596–608. doi:10.1148/rg.2019180159

23. Phillips D, Deipolyi AR, Hesketh RL, Midia M, Oklu R. "Pelvic congestion syndrome: etiology of pain, diagnosis, and clinical management." J Vasc Interv Radiol. 2014;25(5):725–733. doi:10.1016/j.jvir.2014.01.030

24. Jurga-Karwacka A, Karwacki GM, Schoetzau A, et al. "A forgotten disease: pelvic congestion syndrome as a cause of chronic lower abdominal pain." PLoS One. 2019;14(4):e0213834. doi:10.1371/journal.pone.0213834

25. Samplaski MK, Li J, Shoskes DA. "Clustering of UPOINT domains and subdomains in men with chronic prostatitis/chronic pelvic pain syndrome and contribution to symptom severity." J Urol. 2012;188(5):1788–1793. doi:10.1016/j.juro.2012.07.036

26. Franco JV, Turk T, Jung JH, et al. "Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome." Cochrane Database Syst Rev. 2019;10:CD012552. doi:10.1002/14651858.CD012552.pub2

27. Franco JV, Turk T, Jung JH, et al. "Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome." Cochrane Database Syst Rev. 2018;5:CD012551. doi:10.1002/14651858.CD012551.pub3

28. Lam JC, Stokes W. "Acute and chronic prostatitis." Am Fam Physician. 2024;110(1):45–51.

29. Sandhu J, Tu HYV. "Recent advances in managing chronic prostatitis/chronic pelvic pain syndrome." F1000Res. 2017;6:F1000 Faculty Rev-1747. doi:10.12688/f1000research.10558.1

30. Arnold MJ, Osgood AT, Aust A. "Chronic pelvic pain in women: ACOG updates recommendations." Am Fam Physician. 2021;103(3):186–188.

31. Starzec-Proserpio M, Frawley H, Bø K, Morin M. "Effectiveness of nonpharmacological conservative therapies for chronic pelvic pain in women: a systematic review and meta-analysis." Am J Obstet Gynecol. 2025;232(1):42–71. doi:10.1016/j.ajog.2024.08.006

32. Lai HH, Pontari MA, Argoff CE, et al. "Male chronic pelvic pain: AUA Guideline. Part II — treatment of chronic prostatitis/chronic pelvic pain syndrome." J Urol. 2025;214(2):127–137. doi:10.1097/JU.0000000000004565

33. Wang X, Ding N, Sun Y, et al. "Non-pharmacological therapies for treating chronic pelvic pain in women: a review." Medicine (Baltimore). 2022;101(49):e31932. doi:10.1097/MD.0000000000031932

34. Kou L, Huang C, Xiao D, et al. "Pharmacologic interventions for endometriosis-related pain: a systematic review and meta-analysis." Obstet Gynecol. 2025. doi:10.1097/AOG.0000000000005923

35. Alonso A, Gunther K, Maheux-Lacroix S, Abbott J. "Medical management of endometriosis." Curr Opin Obstet Gynecol. 2024;36(5):353–361. doi:10.1097/GCO.0000000000000983

36. Voelker R. "What is endometriosis?" JAMA. 2025. doi:10.1001/jama.2025.14241